The DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index.
Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy
Open accessAbstract
Alzheimer's disease is characterized by amyloid plaques, neurofibrillary tangles, glial activation, and neurodegeneration. In mouse models, inflammatory activation of microglia accelerates tau pathology. The chemokine fractalkine serves as an endogenous neuronal modulator to quell microglial activation. Experiments with fractalkine receptor null mice suggest that fractalkine signaling diminishes tau pathology, but exacerbates amyloid pathology. Consistent with this outcome, we report here that soluble fractalkine overexpression using adeno-associated viral vectors significantly reduced tau pathology in the rTg4510 mouse model of tau deposition. Furthermore, this treatment reduced microglial activation and appeared to prevent neurodegeneration normally found in this model. However, in contrast to studies with fractalkine receptor null mice, parallel studies in an APP/PS1 model found no effect of increased fractalkine signaling on amyloid deposition. These data argue that agonism at fractalkine receptors might be an excellent target for therapeutic intervention in tauopathies, including those associated with amyloid deposition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“tau pathology was reduced by inhibiting microglial activation via overexpression of CX3CL1, a chemokine released by neurons that binds to microglial-expressed CX3CR1 [240] or by administration of anti-inflammatory drugs [113]”
From Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function (2022) · cites this paper as [240]
In the citing paper
“Microglia first sense and clear tau in an attempt to protect from tau toxicity, but dysregulation of microglial sensing and housekeeping pathways, such as the Cx3cr1 and Trem2 pathways, lead to dysregulation of the host-defense pathway, resulting in a neuroinflammatory response gone awry, causing neuronal damage and loss55–57.”
From Microglia in neurodegeneration (2018) · cites this paper as [56]
In the citing paper
“overexpressing a soluble form of CX3CL1, the ligand for CX3CR1, reduces microglial cell activation and tau pathology in rTg4510 mice [G]64.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [64]
In the citing paper
“Similarly, overexpression of soluble CX3CL1 reduces microglial activation and neuronal loss in rTg4510 mice64.”
From Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Self-citationGlutamate neurotoxicity and diseases of the nervous system
Choi, D. W. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 8,188
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
Imai, T., Hieshima, K., Haskell, C. A., Baba, M., Nagira, M., Nishimura, M., Kakizaki, M., Takagi, S., Nomiyama, H., Schall, T. J., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80438-9 · Cited by 1,472
Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
Self-citationWyss-Coray (2006) · doi:10.1038/nm1484 · Cited by 1,284
Harrison, J. K., Jiang, Y., Chen, S., Xia, Y., Maciejewski, D., McNamara, R. K., Streit, W. J., Salafranca, M. N., Adhikari, S., Thompson, D. A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10896 · Cited by 1,176
Cited by
Sorted by citations
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Microglia in neurodegeneration
Hickman, S., Izzy, S., Sen, P., Morsett, L., & El Khoury, J. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0242-x · Cited by 1,710
Tau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight
Shi, Y., & Holtzman, D. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0051-1 · Cited by 595
Tau and neuroinflammation: what impact for Alzheimer's disease and tauopathies?
Laurent, C., Buée, L., & Blum, D. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.003 · Cited by 348
Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis
Henstridge, C. M., Hyman, B. T., & Spires-Jones, T. L. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0113-1 · Cited by 348
Microglia in Health and Disease
Ransohoff, R. M., & Khoury, J. E. (2016) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020560 · Cited by 303
Microglia actions in Alzheimer's disease
Prokop, S., Miller, K. R., & Heppner, F. L. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1182-x · Cited by 291
Laurent, C., Dorothée, G., Hunot, S., Martin, E., Monnet, Y., Duchamp, M., Dong, Y., Légeron, F.-P., Leboucher, A., Burnouf, S., et al. (2017) · Brain · doi:10.1093/brain/aww270 · Cited by 303
The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
Pawelec, P., Ziemka‐Nałęcz, M., Sypecka, J., & Zalewska, T. (2020) · Cells · doi:10.3390/cells9102277 · Cited by 284
Tau in neurodegenerative disease
Gao, Y.-L., Wang, N., Sun, F.-R., Cao, X.-P., Zhang, W., & Yu, J.-T. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.23 · Cited by 222
Targeting Neuroinflammation to Treat Alzheimer’s Disease
Ardura-Fabregat, A., Boddeke, E., Boza‐Serrano, A., Brioschi, S., Castro‐Gomez, S., Ceyzériat, K., Dansokho, C., Dierkes, T., Gelders, G., Heneka, M. T., et al. (2017) · CNS Drugs · doi:10.1007/s40263-017-0483-3 · Cited by 241
Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function
Spiteri, A. G., Wishart, C. L., Pamphlett, R., Locatelli, G., & King, N. J. C. (2022) · Acta Neuropathologica · doi:10.1007/s00401-021-02384-2 · Cited by 216
“[129] generated Cx3cr1CreER:Tak1fl/fl mice, whereby TGF-β-activated kinase 1 (TAK1) was ablated from long-lived CX3CR1+ cells (which include microglia) [129].”
BackgroundInfluentialModulating neurotoxicity through CX3CL1/CX3CR1 signaling
Limatola, C., & Ransohoff, R. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00229 · Cited by 210
Old Maids: Aging and Its Impact on Microglia Function
Koellhoffer, E. C., McCullough, L. D., & Ritzel, R. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040769 · Cited by 213
CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases
Subbarayan, M. S., Joly‐Amado, A., Bickford, P. C., & Nash, K. R. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107989 · Cited by 204
Self-citationIntersection of pathological tau and microglia at the synapse
Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197
Kuhn, P.-H., Colombo, A. V., Schusser, B., Dreymueller, D., Wetzel, S., Schepers, U., Herber, J., Ludwig, A., Kremmer, E., Montag, D., et al. (2016) · eLife · doi:10.7554/elife.12748 · Cited by 163
Brownlow, M. L., Benner, L., D’Agostino, D. P., Gordon, M. N., & Morgan, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075713 · Cited by 153
Self-citationDysregulated phosphoinositide 3-kinase signaling in microglia: shaping chronic neuroinflammation
Chu, E., Mychasiuk, R., Hibbs, M. L., & Semple, B. D. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02325-6 · Cited by 152
CXCL10 Triggers Early Microglial Activation in the Cuprizone Model
Clarner, T., Janssen, K., Nellessen, L., Stangel, M., Skripuletz, T., Krauspe, B., Hess, F.-M., Denecke, B., Beutner, C., Linnartz-Gerlach, B., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401459 · Cited by 150
Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis
Lastres-Becker, I., Innamorato, N. G., Jaworski, T., Rábano, A., Kügler, S., Van Leuven, F., & Cuadrado, A. (2014) · Brain · doi:10.1093/brain/awt323 · Cited by 160
CXCR3 promotes plaque formation and behavioral deficits in an Alzheimer’s disease model
Krauthausen, M., Kummer, M. P., Zimmermann, J., Reyes-Irisarri, E., Terwel, D., Bulic, B., Heneka, M. T., & Müller, M. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66771 · Cited by 152
Formation and Propagation of Tau Oligomeric Seeds
Gerson, J. E., & Kayed, R. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00093 · Cited by 140
Neuroinflammation and fractalkine signaling in Alzheimer’s disease
Finneran, D. J., & Nash, K. R. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1412-9 · Cited by 132
Self-citationFractalkine Signaling and Microglia Functions in the Developing Brain
Arnoux, I., & Audinat, É. (2015) · Neural Plasticity · doi:10.1155/2015/689404 · Cited by 136
Opposing Effects of Membrane-Anchored CX3CL1 on Amyloid and Tau Pathologies via the p38 MAPK Pathway
Lee, S., Xu, G., Jay, T. R., Bhatta, S., Kim, K.-W., Jung, S., Landreth, G. E., Ransohoff, R. M., & Lamb, B. T. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0853-14.2014 · Cited by 123
Microglia in Alzheimer’s Disease in the Context of Tau Pathology
Perea, J. R., Bolós, M., & Ávila, J. (2020) · Biomolecules · doi:10.3390/biom10101439 · Cited by 134
Fractalkine Over Expression Suppresses α-Synuclein-mediated Neurodegeneration
Nash, K. R., Moran, P., Finneran, D. J., Hudson, C., Robinson, J., Morgan, D., & Bickford, P. C. (2014) · Molecular Therapy · doi:10.1038/mt.2014.175 · Cited by 107
Self-citationWes, P. D., Easton, A. E., Corradi, J., Barten, D. M., Devidze, N., DeCarr, L. B., Truong, A. B., He, A., Barrezueta, N. X., Polson, C. T., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106050 · Cited by 106
Joly‐Amado, A., Hunter, J., Quadri, Z., Zamudio, F., Rocha-Rangel, P., Chan, D., Kesarwani, A., Nash, K. R., Lee, D. C., Morgan, D., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00997 · Cited by 105
Self-citationRao, M. V., McBrayer, M. K., Campbell, J., Kumar, A., Hashim, A. T., Sershen, H. W., Stavrides, P. H., Ohno, M., Hutton, M., & Nixon, R. A. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1132-14.2014 · Cited by 101
Thuc, O. L., Blondeau, N., Nahon, J., & Rovère, C. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12855 · Cited by 105
Role of Chemokines in the Development and Progression of Alzheimer’s Disease
Wojcieszak, J., Kuczyńska, K., & Zawilska, J. B. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-022-02047-1 · Cited by 97
The Role of MAPT in Neurodegenerative Diseases: Genetics, Mechanisms and Therapy
Zhang, C., Xing, A., Tan, M., Tan, L., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9415-8 · Cited by 98
Loss of tau rescues inflammation-mediated neurodegeneration
Maphis, N., Xu, G., Kokiko-Cochran, O. N., Cardona, A. E., Ransohoff, R. M., Lamb, B. T., & Bhaskar, K. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00196 · Cited by 91
Fractalkine/CX3CR1 is involved in the cross-talk between neuron and glia in neurological diseases
Luo, P., Chu, S., Zhang, Z., Xia, C., & Chen, N. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.11.017 · Cited by 92
Liu, W., Jiang, L., Bian, C., Liang, Y., Xing, R., Yishakea, M., & Dong, J. (2016) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-016-0395-9 · Cited by 92
Recent Advances in the Study of Bipolar/Rod-Shaped Microglia and their Roles in Neurodegeneration
Au, N. P. B., & Ma, C. H. E. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00128 · Cited by 87
Chamera, K., Trojan, E., Szuster-Głuszczak, M., & Basta‐Kaim, A. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666191113101629 · Cited by 82
Physical Exercise-Induced Myokines in Neurodegenerative Diseases
Lee, B., Shin, M., Park, Y., Won, S.-Y., & Cho, K. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115795 · Cited by 79
Zhou, F., Sun, Y., Xie, X., & Zhao, Y. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01254-1 · Cited by 81
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Jalouli, M., Rahman, M. A., Jeandet, P., Behl, T., Alexiou, A. T., Albadrani, G. M., Abdel‐Daim, M. M., Perveen, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210826130210 · Cited by 76
Hertwig, L., Hamann, I., Romero‐Suárez, S., Millward, J. M., Pietrek, R., Chanvillard, C., Stuis, H., Pollok, K., Ransohoff, R. M., Cardona, A. E., et al. (2016) · European Journal of Immunology · doi:10.1002/eji.201546194 · Cited by 70
Thome, A. D., Standaert, D. G., & Harms, A. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140566 · Cited by 68
CX3CL1/CX3CR1 in Alzheimer’s Disease: A Target for Neuroprotection
Chen, P., Zhao, W., Guo, Y., Xu, J., & Yin, M. (2016) · BioMed Research International · doi:10.1155/2016/8090918 · Cited by 67
Winter, A. N., Subbarayan, M. S., Grimmig, B. A., Weesner, J. A., Moss, L. D., Peters, M. M., Weeber, E. J., Nash, K. R., & Bickford, P. C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01828-y · Cited by 64
Self-citationFan, Q., He, W., Gayen, M., Benoit, M. R., Luo, X., Hu, X., & Yan, R. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1333-19.2019 · Cited by 58
Chemokines in Alzheimer’s Disease: New Insights Into Prokineticins, Chemokine-Like Proteins
Zuena, A. R., Casolini, P., Lattanzi, R., & Maftei, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00622 · Cited by 61
Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A
Liu, J., Wang, D., Li, S.-Q., Yu, Y., & Ye, R. D. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0493-y · Cited by 58
“found that overexpression CX3CL1 in the rTg4510 mouse model directly suppresses tauopathies [46].”
Sustained Arginase 1 Expression Modulates Pathological Tau Deposits in a Mouse Model of Tauopathy
Hunt, J. B., Nash, K. R., Placides, D. S., Moran, P., Selenica, M. B., Abuqalbeen, F., Ratnasamy, K., Slouha, N., Ospina, S. R., Savlia, M., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3959-14.2015 · Cited by 57
Self-citationSandusky‐Beltran, L. A., Kovalenko, A., Ma, C., Calahatian, J. I. T., Placides, D. S., Watler, M., Hunt, J. B., Darling, A. L., Baker, J. D., Blair, L. J., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0507-y · Cited by 51
Self-citationFractalkine/CX3CR1-Dependent Modulation of Synaptic and Network Plasticity in Health and Disease
Camacho-Hernández, N. P., & Peña‐Ortega, F. (2023) · Neural Plasticity · doi:10.1155/2023/4637073 · Cited by 52
McFarland, K. N., & Chakrabarty, P. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01179-3 · Cited by 48
Metabolic changes over the course of aging in a mouse model of tau deposition
Joly‐Amado, A., Serraneau, K. S., Brownlow, M. L., de Evsikova, C. M., Speakman, J. R., Gordon, M. N., & Morgan, D. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.04.013 · Cited by 43
Self-citationBridging the Gap Between Fluid Biomarkers for Alzheimer’s Disease, Model Systems, and Patients
Bjorkli, C., Sandvig, A., & Sandvig, I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00272 · Cited by 41
Glial cells and adaptive immunity in frontotemporal dementia with tau pathology
Hartnell, I. J., Blum, D. L., Nicoll, J. A. R., Dorothée, G., & Boche, D. (2020) · Brain · doi:10.1093/brain/awaa457 · Cited by 41
Critical Molecular and Cellular Contributors to Tau Pathology
Song, L., Wells, E. A., & Robinson, A. S. (2021) · Biomedicines · doi:10.3390/biomedicines9020190 · Cited by 40
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Golde, T. E., Streit, W. J., & Chakrabarty, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt178 · Cited by 39
Janssen, K., Rickert, M., Clarner, T., Beyer, C., & Kipp, M. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9113-6 · Cited by 40
Rodriguez, D., Church, K. A., Pietramale, A. N., Cardona, S. M., Vanegas, D., Rorex, C., Leary, M. C., Muzzio, I. A., Nash, K. R., & Cardona, A. E. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02983-8 · Cited by 37
Self-citationDonison, N. S., Palik, J., Volkening, K., & Strong, M. J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00842-z · Cited by 42
CNS-Wide over Expression of Fractalkine Improves Cognitive Functioning in a Tauopathy Model
Finneran, D. J., Morgan, D., Gordon, M. N., & Nash, K. R. (2019) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9822-5 · Cited by 34
Self-citationComplex role of chemokine mediators in animal models of Alzheimer's Disease
Martin, E., & Delarasse, C. (2018) · Biomedical Journal · doi:10.1016/j.bj.2018.01.002 · Cited by 40
Dysfunctional microglia and tau pathology in Alzheimer’s disease
Ayyubova, G. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0087 · Cited by 36
CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease
Bivona, G., Iemmolo, M., & Ghersi, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098230 · Cited by 35
Role of chemokines in Parkinson's disease
Liu, J., Chu, S., Zhou, X., Zhang, D., & Chen, N. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.05.020 · Cited by 37
Astrocyte subtype-specific approach to Alzheimer's disease treatment
Sarkar, S., & Biswas, S. C. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.104956 · Cited by 35
Pampuščenko, K., Morkūnienė, R., Krasauskas, L., Smirnovas, V., Brown, G. C., & Borutaitė, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-37887-3 · Cited by 31
Effects of the C57BL/6 strain background on tauopathy progression in the rTg4510 mouse model
Bailey, R. M., Howard, J., Knight, J., Sahara, N., Dickson, D. W., & Lewis, J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-8 · Cited by 33
The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases
Iemmolo, M., Ghersi, G., & Bivona, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098026 · Cited by 35
Clayton, E. L., Mancuso, R., Nielsen, T. T., Mizielinska, S., Holmes, H., Powell, N., Norona, F., Overgaard Larsen, J., Milioto, C., Wilson, K. M., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx003 · Cited by 32
Bemiller, S. M., Maphis, N. M., Formica, S. V., Wilson, G. N., Miller, C. M., Xu, G., Kokiko-Cochran, O. N., Kim, K.-W., Jung, S., Cannon, J. L., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1310-6 · Cited by 24
Oligomeric tau-targeted immunotherapy in Tg4510 mice
Schroeder, S. K., Joly‐Amado, A., Soliman, A. S., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0274-6 · Cited by 24
Self-citationImmunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
Grimmig, B., Morganti, J., Nash, K., & Bickford, P. (2016) · Brain Sciences · doi:10.3390/brainsci6040041 · Cited by 17
Self-citationThe innate immune response in tauopathies
Johnson, A. M., & Lukens, J. R. (2023) · European Journal of Immunology · doi:10.1002/eji.202250266 · Cited by 22
Concentration and proteolysis of CX3CL1 may regulate the microglial response to CX3CL1
Finneran, D. J., Li, Q., Subbarayan, M. S., Joly‐Amado, A., Kamath, S. G., Dengler, D. G., Gordon, M. N., Jackson, M. R., Morgan, D., Bickford, P. C., et al. (2022) · Glia · doi:10.1002/glia.24269 · Cited by 18
Self-citationAge-dependent changes on fractalkine forms and their contribution to neurodegenerative diseases
Eugenín, J. L., Bernhardi, L. E.-V., & Rommy von Bernhardi, M. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1249320 · Cited by 19
CX3CL1 Regulation of Gliosis in Neuroinflammatory and Neuroprotective Processes
Gutiérrez, I. L., Martín‐Hernández, D., MacDowell, K. S., García‐Bueno, B., Caso, J. R., Leza, J. C., & Madrigal, J. L. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030959 · Cited by 20
Proinflammatory cytokines and their receptors as druggable targets to alleviate pathological pain
Kalpachidou, T., Riehl, L., Schöpf, C. L., Uçar, B., & Kress, M. (2022) · Pain · doi:10.1097/j.pain.0000000000002737 · Cited by 17
Stothert, A. R., & Kaur, T. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.694292 · Cited by 15
Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review
Dunning, E. E., Decourt, B., Zawia, N. H., Shill, H. A., & Sabbagh, M. N. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00614-9 · Cited by 20
Inflammatory protein associations with brain MRI measures: Framingham Offspring Cohort
Chen, J., Ragab, A. A. Y., Doyle, M. F., Alosco, M. L., Fang, Y., Mez, J., Satizábal, C. L., Qiu, W. Q., Murabito, J. M., & Lunetta, K. L. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14147 · Cited by 12
Chen, P., Yan, Q., Wang, S., Wang, C., & Zhao, P. (2016) · Gene · doi:10.1016/j.gene.2016.04.032 · Cited by 14
Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina
Rodriguez, D., Church, K. A., Smith, C. T., Vanegas, D., Cardona, S. M., Muzzio, I. A., Nash, K. R., & Cardona, A. E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031727 · Cited by 14
Self-citationTherapeutic Targets in Innate Immunity to Tackle Alzheimer’s Disease
Serradas, M. L., Ding, Y., Martorell, P., Kulińska, I., & Castro‐Gomez, S. (2024) · Cells · doi:10.3390/cells13171426 · Cited by 16
Quadri, Z., Johnson, N. J., Zamudio, F., Miller, A., Peters, M. M., Smeltzer, S., Hunt, J. B., Housley, S. B., Brown, B., Kraner, S. D., et al. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103418 · Cited by 8
Self-citationManickam, V., Maity, S., Murali, S. V., Gawande, D. Y., Stothert, A. R., Batalkina, L., Cardona, A. E., & Kaur, T. (2024) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2024.1486740 · Cited by 7
Osting, S., Bennett, A. D., Power, S., Wackett, J., Hurley, S. A., Alexander, A. L., Agbandje‐McKenna, M., & Bürger, C. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.4 · Cited by 7
Takuwa, H., Orihara, A., Takado, Y., Urushihata, T., Shimojo, M., Ishikawa, A., Takahashi, M., Barron, A. M., Ono, M., Maeda, J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.11.04.368977 · Cited by 6
Microglial Drivers of Alzheimer's Disease Pathology: An Evolution of Diverse Participating States
Kuhn, M. K., & Proctor, E. A. (2024) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26723 · Cited by 5
Wolf, T., Moss, L. D., Hudson, C., Winters, A. M., Abdelmaboud, S. S., Avlas, M., Wohlfahrt, J., Guergues, J., Bickford, P. C., & Stevens, S. M. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70034 · Cited by 4
Self-citationAutomatic stereology of mean nuclear size of neurons using an active contour framework
Phoulady, H. A., Goldgof, D. B., Hall, L., Nash, K. R., & Mouton, P. R. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2018.12.012 · Cited by 4
Self-citationADAM proteases in cytokine biology: Modulators of immune signaling, inflammation and cancer
Khattab, H., Solujic, J., & Saad, M. I. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2026.120137 · Cited by 4
Cimiotti, C. G. V., Paganetti, P., Rossi, S., Soldini, E., & Sacco, L. (2023) · NeuroSci · doi:10.3390/neurosci4040026 · Cited by 3
Bang-feng, L., Chen, X., Xie, R., Mo, Y.-F., Wu, Y.-Z., Meng, Y., Han, X.-L., Chen, M., & Peng, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1818802 · Cited by 2
Gruol, D. L. (2017) · MDPI eBooks · doi:10.3390/books978-3-03842-571-7 · Cited by 1
Diet-Induced Ketosis and Calorie Restriction in Mouse Models of Alzheimer's Pathology
Brownlow, M. L. (2013) · Digital Commons - University of South Florida (University of South Florida)
Self-citationLinking CD200 in brains and dementia
Walker, D. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00023-2
Chung, D. C., Stankowski, J. N., & Petrucelli, L. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0056
Metadata
- Authors
- Nash, K. R., Lee, D. C., Hunt, J. B., Morganti, J. M., Selenica, M.-L., Moran, P., Reid, P., Brownlow, M., Guang-Yu Yang, C., Savalia, M., Gemma, C., Bickford, P. C., Gordon, M. N., & Morgan, D.
- Affiliations
- University of South Florida (US)
- University of California, San Francisco (US)
- University of Washington (US)
- Corresponding author
- Nash, Kevin R.
- ORCID
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 34
- Issue
- 6
- Pages
- 1540-1548
- ISSN
- 0197-4580 (ISSN-L)
- PMC
- PMC8970215
- OpenAlex
- W2144997087
- Cited by
- 108
- References
- 50
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 10 · 2023: 8 · 2022: 5 · 2021: 8 · 2020: 8 · 2019: 11 · 2018: 8 · 2017: 7 · 2016: 9 · 2015: 10 · 2014: 9 · 2013: 7
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH/NIA (R01 AG025509, NIH NS76308, NIH AG15470)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- fractalkine, tau pathology, tauopathy, Alzheimer's disease, microglial activation, neuroinflammation, adeno-associated virus vectors, amyloid deposition, APP/PS1 mice, neurodegeneration, chemokines
- MeSH terms
- Animals, Disease Models, Animal, Gene Expression Regulation, Mice, Transgenic, tau Proteins, Tauopathies, Mice, Chemokine CX3CL1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
